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Purpose: The aim of this study was to investigate the application of the three-dimensional 
bone bioreactor for studying drug-release kinetics and distribution of drugs in the ex vivo 
cancellous bone environment, and to demonstrate the application of nanoengineered titanium 
(Ti) wires generated with titania nanotube (TNT) arrays as drug-releasing implants for local 
drug delivery
Methods: Nanoengineered Ti wires covered with a layer of TNT arrays implanted in bone 
were used as a drug-releasing implant. Viable bovine trabecular bone was used as the ex vivo 
bone substrate embedded with the implants and placed in the bone reactor. A hydrophilic fluo-
rescent dye (rhodamine B) was used as the model drug, loaded inside the TNT–Ti implants, to 
monitor drug release and transport in trabecular bone. The distribution of released model drug 
in the bone was monitored throughout the bone structure, and concentration profiles at different 
vertical (0–5 mm) and horizontal (0–10 mm) distances from the implant surface were obtained 
at a range of release times from 1 hour to 5 days.
Results: Scanning electron microscopy confirmed that well-ordered, vertically aligned nano-
tube arrays were formed on the surface of prepared TNT–Ti wires. Thermogravimetric analysis 
proved loading of the model drug and fluorescence spectroscopy was used to show drug-release 
characteristics in-vitro. The drug release from implants inserted into bone ex vivo showed a 
consistent gradual release of model drug from the TNT–Ti implants, with a characteristic three-
dimensional distribution into the surrounding bone, over a period of 5 days. The parameters 
including the flow rate of bone culture medium, differences in trabecular microarchitecture 
between bone samples, and mechanical loading were found to have the most significant influ-
ence on drug distribution in the bone.
Conclusion: These results demonstrate the utility of the Zetos™ system for ex vivo drug-
release studies in bone, which can be applied to optimize the delivery of specific therapies and 
to assist in the design of new drug delivery systems. This method has the potential to provide 
new knowledge to understand drug distribution in the bone environment and to considerably 
improve existing technologies for local administration in bone, including solving some critical 
problems in bone therapy and orthopedic implants.
Keywords: local drug delivery, Zetos bone bioreactor, drug-releasing implant, drug 
diffusion
Introduction
Bone diseases are a major health problem worldwide. They have a highly deleteri-
ous effect on both quality of life for patients and health expenditure, representing at 
least 10% of annual health care expenditure in many developed countries.1 A number 
of therapeutic approaches have been developed to treat bone diseases, and these 
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are dominated by the use of systemic drug administration. 
However, conventional systemic drug therapies have many 
limitations, both in general and in bone, such as low efficacy, 
poor bioavailability and biodistribution, lack of selectivity, 
and drug overdose and toxicity in nontarget tissues.2,3 To 
overcome these limitations, increase drug effectiveness, and 
reduce systemic side effects of drugs, localized delivery of 
therapeutics to bone has been recognized as a promising 
alternative.4,5 Local drug delivery offers many potential 
advantages, leaving healthy cells or adjacent tissues at other 
sites unaffected and avoiding serious side effects, providing 
locally optimal concentrations of often expensive drugs 
without diluting them across the entire body, and optimizing 
bioavailability, without rapid breakdown and clearance of 
drugs, particularly through the liver uptake.6
The concept of a skeletal drug delivery system was first 
introduced by Buchholz et al7 in the 1970s and has been 
extensively explored since. The development of biocompatible 
drug-releasing materials and appropriate models to study 
drug release from these systems, and their effectiveness in 
bone prior to in vivo study, are recognized as critical issues 
to be addressed.8,9 Numerous biomaterials, either natural or 
synthetic, and either biodegradable or biologically inert, such 
as polymethyl methacrylate, poly(lactic-co-glycolic acid), 
collagen, hyaluronan, chitosan, fibrin, silk, hydroxyapatite, 
ceramics and injectable calcium phosphate cements, in the 
form of membranes, granules, hydrogels, matrices, coatings, 
fibers, sponges, and foams, have been explored in recent years 
as implants for the delivery of bone active agents.10–15 These 
materials are mostly amorphous, with a large variation of 
porosity and nonreproducible preparation, which in turn makes 
the bone therapy nonreproducible.15 In most cases, these implants 
are designed for the delivery of specific drugs and do not have 
the flexibility to be applied to a wide range of therapeutic agents, 
such as water-insoluble drugs, drug carriers, or labile agents 
(proteins and genes). To address these disadvantages, several 
new nanosynthetic and surface-engineered approaches have 
been applied for the development of advanced drug-releasing 
materials and devices with controllable pore size, porosity, 
and surface functionality at the nanoscale level.5,6,16 Among 
them, titania nanotube (TNT) arrays, generated on titanium 
(Ti) surfaces by self-ordered electrochemical anodization, 
are recognized as a particularly promising solution.17,18 TNTs 
have been proven to have many favorable features, including 
biocompatibility, excellent integration with bone tissue, an 
ability to promote the growth of hydroxyapatite, high surface 
area, controllable pore dimensions, surface chemistry, chemical 
stability, and mechanical rigidity.18–21
The second issue of local drug delivery in bone is that 
most studies of drug release relevant to bone therapies have 
been performed using in vitro conditions, where the drug-
loaded implant is interfaced with the solution (buffer) or 
with cultured bone cells. However, bone is a complex porous 
material consisting of a solid bone matrix and pore spaces. 
Two types of bone can be distinguished: compact (or cortical) 
bone with small pore spaces (Haversian canals) and spongy 
(or cancellous) bone with large pore spaces filled with bone 
marrow. The three major types of bone cells are osteoblasts, 
osteoclasts, and osteocytes.22 It is not known how drug release 
in solution relates to drug release in bone tissues, given that 
cancellous bone is a highly hydrated tissue, with abundant 
interstitial fluid surrounded by marrow with a high fat 
content.5,23 Hence, in order to evaluate the potential of local 
drug delivery systems, the authors sought a suitable system. 
Because studies in live bone tissue in situ are technically dif-
ficult and expensive, the use of an ex vivo bone bioreactor, 
consisting of a trabecular bone explant, was explored as a 
suitable alternative. Recently, several three-dimensional (3D) 
bone reactors have been developed and explored to study the 
biological aspect of bone cell behavior and bioengineering 
of bone tissues, including the Zetos system.23–25 The Zetos 
system, devised by David Jones (Department of Experimen-
tal Orthopaedics and Biomechanics, Philipps University of 
Marburg, Marburg, Germany) and Everett Smith (Medical 
Sciences Center, Madison, WI), enables discs of cancellous 
bone to be maintained for at least 3 weeks by continuous 
perfusion with culture medium and daily loading with physi-
ologically relevant strains.24–26
The aim of this study was to assess the Zetos bone bio-
reactor for ex vivo study of drug distribution in bone and 
to demonstrate the application of nanoengineered Ti wires 
generated with TNT arrays (TNT–Ti wires) as drug-releasing 
implants for local drug delivery (Figure 1A and B). The TNT 
layer is composed of an array of highly ordered, vertically 
aligned nanotubes with the capacity to accommodate and 
release a considerable amount of drug.18–20 In previous work, 
the authors have developed TNT–Ti wires with advanced 
properties to provide extended and sustained drug release 
with zero-order kinetics, multidrug delivery with sequential or 
delayed release, and stimuli-responsive release of drugs using 
a magnetic field.27–31 In the present study, the TNT–Ti wires 
were loaded with the fluorescence dye (rhodamine B [RhB]) 
as a model drug and inserted into the middle of trabecular 
bone discs (Figure 1C), which were placed inside the bone 
bioreactor with continuous perfusion of culture medium 
(Figure 1D). The Xenogen IVIS® 100 BioPhotonic Imaging® 
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system (Caliper Life Sciences, Inc, Hopkinton, MA) was used 
to monitor in vivo drug release and distribution inside the bone 
matrix over time (from 1 hour to 5 days). The purpose was to 
demonstrate the capacity of the Xenogen system to provide 
in situ measurements of drug release from the implant and 
to determine the 3D spatial distribution of drugs in bone, the 
drug-release rate, and drug-release kinetics.
Materials and methods
Materials
Alfa Aesar (Ward Hill, MA) supplied the Ti (99.99%) 
wires (diameter 0.75 mm). Ethylene glycol, acetone, 








, with 97% 
dye content) were obtained from Sigma-Aldrich Pty Ltd 
(Sydney, Australia) and used without further purification. 
High-purity, ultra-grade Milli-Q® water (18.2 MΩcm resis-
tivity) (EMD Millipore Corporation, Billerica, MA) with 
additional filtration (0.22 µm) was used for the preparation 
of all reagents.
Preparation of TNT–Ti wires  
as drug-releasing implants
Ti wires were cut to size (approximately 10 mm in length), 
polished, cleansed ultrasonically with acetone, rinsed thor-
oughly with deionized Milli-Q water, and air-dried. TNT 
layers were then prepared by a two-step electrochemical 
anodization of Ti wires in ammonium fluoride/ethylene 
glycol electrolyte (3% water and 0.3% ammonium fluoride) 
at 20°C, using a constant voltage of 100 V for 1 hour, as 
described previously.32–34 Both pore diameter and length 
of the TNTs were determined by selecting the appropriate 
 voltage (100 V) and anodization time (1 hour).
Structural characterization of prepared 
TNT–Ti wires
Structural characterization of the prepared TNT–Ti wires 
was performed before and after drug loading and drug-
release experiments in bone using a field emission scanning 
electron microscope (SEM) (Philips XL 30; Philips Research 
Eindhoven, Eindhoven, The Netherlands). The samples 
were cut into small pieces, (approximately 5 mm in length) 
mounted on a holder with double-sided conductive tape, and 
coated with a layer of platinum 3–5 nm thick. Images, with 
a range of scan sizes at normal incidence and at a 30° angle, 
were acquired from the top surface, the bottom surface, and 
cross-sections.
Loading of the model drug
RhB, the model drug in this study, was dissolved in water 
(50 mg/mL) and used for loading into the TNT–Ti wires. 
TNT–Ti wires cut into 8 mm lengths were fully immersed in 
the RhB solution to ensure drugs were entirely loaded inside 
the nanotubes. The wires were rotated every 2–4 hours during 
RhB deposition. After 1–3 days of loading, the wires were 
removed, dried in air, and then kept under vacuum for 2 hours. 
Finally, to remove the excess of loaded drug from the TNT 
surfaces, samples were gently cleaned with a soft tissue after 
wetting with a small amount of phosphate buffered saline 
(pH 7.2). The wires were sterilized using low-temperature 
hydrogen peroxide gas plasma (Sterrad® 100NX™ System, 
Advanced Sterilization Products (ASP),Division of Ethicon 
Inc, a Johnson & Johnson company, Irvine, CA).
Quantification of drug loading
To quantify the amount of RhB loaded into the TNT–Ti wires, 
thermogravimetric analysis (TGA), which measures the mass 
change (weight loss) in a sample as a function of temperature, 
was performed using a Hi-Res Modulated TGA 2950 (TA 
Instruments, New Castle, DE). The drug-loaded TNT–Ti 
wire was mounted on the platinum pan and heated from room 
temperature (at 20°C) to 800°C in a furnace at a scanning rate 
of 10°C per minute under a nitrogen gas flow of 50 mL per 
minute. To find the correct decomposition range and peak of 
RhB model drugs, TGA of the pure RhB was performed in 
separate experiments. A thermogram showing a decrease in 
weight was identified from the TGA software (Q Series Ther-
mal Analysis, Universal Analysis 2000; TA Instruments) and 














































Figure 1 (A) Diagram of a titanium (Ti) wire with titania nanotube (TNT) 
arrays on the surface as a drug-releasing implant; (B) diagram of the TNT arrays 
formed by anodization of the Ti wire and the drug loading inside these nanotubes; 
(C) trabecular bone with the embedded TNT–Ti implant indicated in the center of 
the bone core (side and top views); (D) bioluminescence image of the bone core 
and the embedded TNT–Ti implant inside the perfusion chamber – the distribution 
of released drug inside the bone is also shown.
Abbreviation: TiO2, titanium dioxide.
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Preparation of bovine trabecular bone 
cores
The sternum of a 16-month-old steer was harvested from 
the freshly slaughtered animal and kept in cold sterile saline 
(0.85%) prior to processing. All soft tissues were removed 
from the sternum, which was then manually cut into sagittal 
sections using a hacksaw. Care was taken to maintain the 
sterility and viability of the samples at all times. Prepared 
sections were kept immersed in a prewash medium, consisting 
of high-glucose Dulbecco’s Modified Eagle Medium (Life 
Technologies Corporation, Carlsbad, CA), with 20 mM of 
4-(2-hydroxyethyl)-piperazineethanesulfonic acid, 2.4 mg/mL 
of benzylpenicillin, 3.2 mg/mL of gentamicin  sulfate, and 
4 µg/mL of amphotericin B. Bone cylinders, 10 mm in 
diameter, were prepared from the bone sections using an 
industrial drilling machine (Model G0517 Mill/Drill, Grizzly 
Industrial®, Inc, Muncy, PA) and a custom-made diamond drill 
bit (Figure 2A). Bone samples were continually immersed 
in cold sterile saline (0.85%) on a custom-made polyoxym-
ethylene drilling jig to prevent desiccation and/or thermal 
necrosis. The bone cylinders were mounted onto a custom-
made platform and milled to a 5 mm thickness using a 10 mm 
diameter tungsten carbide bit, with the bone pieces immersed 
throughout in cold sterile saline (0.85%). The resulting bone 
cores consisted of uniform trabecular bone without any vis-
ible cartilage. All bone cores had the marrow removed by 
washing under pressure using a dental water jet (WP-450A; 
Water Pik, Inc, Fort Collins, CO). The bone cores were stored 
in the prewash medium at 4°C prior to use.
In vitro drug release from TNT–Ti 
implants
The RhB-loaded TNT–Ti wires were immersed in 5 mL 
of phosphate buffered saline (pH 7.2) at room temperature 
and an in vitro drug-release study was performed, using a 
procedure described previously.27 Briefly, aliquots of buffer 
solution were analyzed every 5–15 minutes and then twice 
daily until the release reached completion. The aliquots 
were placed in a quartz cuvette and the concentration of 
released RhB was measured using a Cary Eclipse fluores-
cence spectrophotometer (Varian, Inc, Palo Alto, CA) with 
excitation and emission wavelengths of 510 and 625 nm, 
respectively.
Insertion of TNT–Ti wires  
into the bovine bone cores
A hole was drilled through each bone core using a sterilized 
1.1 mm diameter Kirschner wire (surgical grade stainless steel 
sharp pin) (Figure 2A). A TNT–Ti wire was  carefully inserted 
into the hole, fitting tightly into the center of the bone core 
(Figure 2B), and the bone was secured in the custom-made 
culture chamber, as shown in Figure 2C. The orientation of 
the implants inside the bones connected to the inlets and 
outlets of the bioreactor was kept the same for all samples 
(Figure 2C). Bone cores were then loaded into the sterile 
perfusion chambers that were compatible with the Zetos™ 
loading system (Figure 3). The study was performed with and 
without different mechanical loading, but only results without 
loading have been presented, because of data congestion.
Ex vivo drug release in trabecular bone
Six trabecular bone cores, four with TNT–Ti wires loaded with 
RhB and two with TNT–Ti wires without RhB, were prepared 
and perfused with culture medium during the course of this 
study. The study was performed in triplicate. The 3D bone 
bioreactor comprises a set of cross-flow culture chambers, 
allowing a constant perfusion of bone samples with culture 
medium at a rate of 7 mL per hour (Figure 3). The entire 
apparatus was maintained at 37°C. The color intensity of 
the dye from the TNT–Ti wires and into the bone core was 
measured at 1, 4, and 24 hours and 4 and 5 days (Figure 1D) 
using the Xenogen IVIS 100 (In vivo imaging system). This 
measurement provided an accurate estimate of the amount 
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Figure 2 Steps for preparation of bovine trabecular bone cores for ex vivo studies using 
the Zetos three-dimensional bone bioreactor: (A) bone core with marrow removed 
and a hole in the center drilled with a surgical Kirschner wire; (B) drug-releasing 
implant, based on a titanium (Ti) wire with titania nanotube (TNT) arrays on the 
surface, embedded in the center of the bone; (C) the bone core with implant placed 
inside the chamber with the same orientation (angle) to the flow of prelusion medium 
into the bone; (D) diagram of bone core showing inserted implant in the middle and 
the directions (with different axes) used to monitor drug concentration. 
Note: In this work, only drug distribution from the central point of the implant (0) at 
the bottom vertical plane (x-z) and the horizontal plane (x-y) is presented.
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the color intensity (photons/second/cm2). The luminescence 
imaging mode was set at an exposure time of 1 minute, with 
medium-size binning, open emission filter, and 25 cm view 
field. The dimension of the pixel count was 2 × 2 (width by 
height), with a subject area of 0.76 cm2. The photon count rate 
per unit area, based on the control samples with dye and no 
dye, was used as the benchmark for the diffusion measurement 
in terms of the time and spatial distance across the bone. The 
drug concentration values from the collected images were 
obtained by calibration, using the known concentration of 
the model drug on the TNT–Ti wire surface and the control 
wire with no drug. The parameter mass flux (mg/cm2 ⋅ second) 
was calculated from the number of photons collected as the 
RhB dye passed through a unit area by a linear conversion of 
units. Molar flux (mol/cm2 ⋅ second), mass flow (mg/second), 
and volumetric flow rate (mL/second) can also be derived 
from the primary data available from the results. From these 
images, the values of drug concentration in bone at different 
distances along the x, y, and z axes from the center of the bone 
(position of the implant) over time (from 1 hour to 5 days) 
were obtained. These results can be used to create 3D drug 
distribution graphs, but in this study only two-dimensional 
concentration profiles in the horizontal and vertical directions 
from the TNT–Ti implant surface are presented to demonstrate 
the capability of the system.
Results and discussion
Structural characterization of TNT–Ti 
wires
The structure of prepared TNT–Ti wires was characterized 
by SEM and the typical morphology of the wires is summa-
rized in Figure 4. Figure 4A shows the whole TNT–Ti wire 
(12 mm) (inset) and a low-resolution SEM image confirm-
ing the growth of a TNT film on the curved surface of the 
Ti wire. The SEM image shows randomly dispersed vertical 
cracks across the entire length of the wire, caused by the 
radial growth of TNTs on the curved surface and mechanical 
stress through volume expansion. These cracks have not been 
observed on TNT films grown on planar Ti surfaces.  However, 
the generation of TNTs on wire did not significantly change 
the original mechanical stability and adherence of the TNT 
layer on Ti. High-resolution SEM images of the top surface, 
cross-section, and bottom surface of the TNT layer show 
a vertically aligned and densely packed array of uniform 
nanotubes, with diameters of 140 ± 10 nm and lengths of 
50 ± 2 µm, across the entire structure ( Figure 4B–D). TNT–
Ti wires occupy a very small amount of space and are easy 
to implant into bone and be removed. These features show 
many advantages for implantable orthopedic applications in 
comparison with existing commercial bone implants such as 
polymer gels and bone cements.
The in vitro drug-release characterization
TGA was performed to determine the amount of drug 
loaded into the nanotubular structures of the TNT–Ti 
wires. A total RhB loading of 0.27 mg was found per 
8 mm length of TNT–Ti wire. However, the drug loading 
of TNT–Ti wires can be optimized by selecting appropri-
ate TNT dimensions and applying surface modifications.35 
Thus, it is possible to customize TNT–Ti platforms to 
meet specific requirements for implantable drug delivery 
in bone, depending on the required dosage, properties of 
drugs, and proposed bone therapy (infections, bone cancer, 
and so forth).
Peristaltic pump
Culture fluid reservoirsPerfusion chambers
Bone loader
Figure 3 The Zetos three-dimensional bone bioreactor (devised by David Jones 
[Department of Experimental Orthopaedics and Biomechanics, Philipps University 
of Marburg, Marburg, Germany] and Everett Smith [University of Wisconsin, WI]) 
used for the ex vivo study of drug distribution inside trabecular bone.
Figure 4 Scanning electron microscope images of (A) a drug-releasing implant 
based on a titanium (Ti) wire with titania nanotube (TNT) arrays on the surface 
(whole wire shown in inset), (B) the top surface of the TNTs, (C) a cross-sectional 
view showing hollow nanotube structures, and (D) the bottom surface, showing 
closed ends of the nanotube structures (the TNT layer was removed from the 
underlying Ti for imaging purposes).
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In vitro drug release of the model drug (RhB) loaded into 
the TNT–Ti wires in buffer solution is presented in Figure 5. 
The drug-release kinetics can be described in two phases, the 
first phase showing an initial burst release during the first 
6 hours, followed by the second phase with a slow release of 
the remaining drug. The initial burst denoted by the straight 
portion of the curve, with a release of about 65% in buffer 
solution, is regarded as a first-order release. The fast initial 
release accounts for the fast diffusion of the drug molecules 
physisorbed on the top and upper parts of the TNTs. In the 
second phase, drug release from the TNT–Ti implant was 
very slow and underwent a linearly increasing cumulative 
release over a period of 3 days. The release mechanism of 
this phase is controlled by diffusion from the long nanotube 
structures.36,37 The best-fitting model for this phase was 
obtained using the Higuchi equation followed by the zero-
order release, which describe drug release from an insoluble 
matrix.38 The square root of a time-dependent process is based 
on the Fickian diffusion law, where the diffusion-controlled 
release rate of drug molecules decreases as a function of time 
due to a reduction in concentration gradient. The pharma-
ceutical dosage following a zero-ordered pattern is the ideal 
profile of drug release because it provides the same amount of 
drug elution per unit of time.30 These results confirmed previ-
ous reports showing suitable drug-releasing characteristics of 
TNT–Ti implants as drug-releasing platforms for local drug 
delivery applications.39,40 In the following section, the authors 
investigate the performance of the TNT–Ti implants when 
implanted in trabecular bone in a bioreactor environment.
The characterization of drug diffusion  
in trabecular bone ex vivo
The structure of bone is complex and is expected to have a 
significant impact on both drug-release kinetics and drug 
distribution in bone. Bioluminescence images created at 
different times (ie, 1, 4, 24, and 120 hours) for the 5-day 
experiment on drug-release studies using the Xenogen IVIS 
(in vivo imaging system) are presented in Figure 6. Results 
clearly show an increasing concentration of the model drug 
within the bone model. To demonstrate drug release in the 
3D bone matrix, a series of drug concentration profiles were 
collected from these images. These profiles show the changes 
of drug concentration in bones across all directions (x, y, and 
z axes) from the TNT–Ti implant. To simplify the presentation 
of results, only two-dimensional concentration profiles of the 
drug in vertical (x-z) and horizontal (x-y) directions from the 
implant are presented in this work (Figure 7). The graphs 
show significant changes in RhB concentration in bone over 
time, confirming that both processes, ie, the diffusion of 
RhB from the TNT–Ti implants and the diffusion of RhB 
into bone, occurred. Initially, the release of RhB from the 
TNT–Ti implants followed burst release kinetics (Figure 5), 
and the highest concentration of RhB was observed at loca-
tions close to the implant surface, with zero concentration at 
greater distances from the implant. Over time, as more RhB 
was released, the concentration increased further from the 
implant, showing the spread of RhB across the bone tissue 
in all directions (results for only two directions, vertical and 
horizontal, are presented). After 4 and 5 days of release, the 
highest concentration was observed at the outer locations of 
the bone, which was 3.5–5 mm away from the surface of the 
implant, showing a concentration of nearly 15–20 µg. After 
5 days of release, there was no measurable drug remaining in 
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Figure 5 In vitro drug release from implants (based on titanium wires with titania 
nanotube arrays on their surfaces) into phosphate buffer.
Figure 6 Bioluminescence images of bone with inserted drug-releasing implant 
(based on a titanium wire with titania nanotube arrays on the surface) for local drug 
delivery: distribution of released model drug (rhodamine B) taken at (A) 1, (B) 4, 
(C) 24, and (D) 120 hours (h) using the Xenogen IVIS® 100 (Caliper Life Sciences, 
Inc, Hopkinton, MA) in vivo imaging system.
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with the diffusion of RhB into the bone tissue. The graphs 
also show that the spatial RhB distribution in bone is not 
uniform, which is likely explained by the variable nature 
of the internal bone microarchitecture and the influence of 
culture medium flow inside the bone chamber.23
The effects of perfusion of culture 
medium on the drug diffusion pattern
A continuous flow chamber with culture medium was used 
in the bone bioreactor to simulate in vivo conditions, mim-
icking bone fluid flow and maintaining bone viability. It is 
reasonable to expect that the flow of culture medium at the 
interface between bone and the TNT–Ti implant will influ-
ence the release kinetics of the drug from the TNTs and have a 
significant impact on drug distribution. To confirm the impact 
of flow on drug transport in the bone, the authors performed 
a control experiment without culture flow. The comparative 
concentration graphs obtained at different distances from the 
implant at vertical and horizontal directions unequivocally 
show a difference in diffusion kinetics when external flow 
is not applied (Figure 8). The drug concentration at both 
horizontal and vertical directions when perfusion was used 
was significantly greater than in static conditions, where drug 
distribution was generated not only by the free diffusion of 
the drug. This result suggests that the diffusion of drug in 
bone is a very slow process and should be considered in drug 
delivery for bone therapy where the access of a drug to bone 
sites without blood supply is required.
Data analysis of the concentration patterns of RhB in 
bone from a number of samples showed some unexpected 
differences and inconsistencies that cannot be linked to the 
influence of medium flow. The authors assumed these dif-
ferences were attributed to differences in trabecular micro-
architecture between bone samples; addressing this issue is 
outside the scope of this paper and will be presented in the 
next publication. When bone samples containing TNT–Ti 
implants were loaded by applying physiologically relevant 
mechanical strains, drug diffusion was increased (data not 
shown); these results will also be presented in a following 
publication. Therefore, bone loading, together with the pres-
ence of the vasculature, is likely to change the drug diffusion 
kinetics, although in vivo models will be required to fully 
investigate drug release and diffusion in situ.
The ex vivo study of drug-release kinetics 
in a 3D bone environment
Finally, to demonstrate the utility of the Zetos bone bio-
reactor for studying drug-release kinetics in bones, two 
examples showing changes of cumulative drug release 
in bone over time are presented in Figure 9. The graphs 
show cumulative drug release in bone over a period of 
time (from 1 hour to 5 days) at three different distances in 
vertical (z) and horizontal (x) directions from the surface 
of the TNT–Ti implant. The drug-release kinetics in buf-
fer solution showed significant differences compared with 
release from TNT–Ti implants in the ex vivo bone. An 
initial burst release (6 hours), with 65% of the cumulative 
release and the first-order release kinetics, was observed for 
in vitro release of RhB into the buffer solution (Figure 5). 
In comparison, ex vivo release in bone showed consider-
ably lower initial release (,20%), without burst release. 
Drug release over this time was slow, with a continuous 
and gradual cumulative increase over time. This behavior 
is likely governed by the diffusion of drug from the TNTs, 
flow rate of culture medium at the TNT–Ti interface, and 
flow rate of culture medium across the bone. The release 
pattern of drug inside the bone follows first-order kinet-
ics in all directions from the implant surface, but some 
anomalies were shown after 3 days in the vertical direc-
tion (z = 0). This is possibly the result of the accumulation 
of RhB at the edge of the bone sample. At this stage, the 
authors cannot quantitatively explain the drug-release 
Figure 7 Two-dimensional concentration graphs of the model drug (rhodamine 
B [RhB]) released from implants based on titania nanotube (TNT) arrays on the 
surface of titanium (Ti) wires. The graphs show spatial distribution in the trabecular 
bone samples: drug distribution is presented at (A) the vertical (vert) plane (x-z) of 
the bottom part of the bone and (B) the horizontal (horizont) plane (x-y) from the 
implant surface at different release times (1, 4, 24, 96, and 120 hours [h]). 
Note: The concentration changes are presented only for a selected area of bone 
(one quadrant), as illustrated in the bone diagrams (left and right).
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kinetics and transport of the model drug in the trabecular 
bone samples, owing to the complex interactions of trans-
port mechanisms, including the diffusive and advective 
components. The importance of this current study is to 
demonstrate the capability of the ex vivo bone system to 
generate valuable experimental data. These data can not 
only be used to define the transport kinetics of drugs in 
bone but also to optimize drug-release characteristics of 
bone implants using TNT technology. Future work will 
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Figure 8 Influence of the physiological solution (culture medium) flow rate in the bone bioreactor on the distribution of the model drug (rhodamine B [RhB]) released from 
implants based on titania nanotube arrays on the surface of titanium wires. The flow rate of 7 mL/hour was compared with the static condition (no flow) after 24 hours 
of drug release. The bone diagrams on the right indicate the locations at (A) horizontal (5 mm) and (B) vertical distances (2.5 mm) from the surface of the implant where 
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Figure 9 Cumulative release of the model drug (rhodamine B) from drug-releasing implants (based on titania nanotube arrays on the surface of titanium wires) in trabecular 
bone, showing changes of concentration at different times (from 1 hour to 5 days). The concentration changes over time are presented for selected locations at (A) vertical 
(x-z) and (B) horizontal (x-y) distances from the surface of the implant.
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influence of flow rate, mechanical loading, an optimization 
of the design of the bioreactor.
Conclusion
In summary, the concept of using a Zetos three-dimensional 
bone bioreactor as a characterization tool for the ex vivo 
study of drug-release kinetics and drug distribution in bone 
was introduced. Viable bovine trabecular bone was used as 
the ex vivo bone substrate embedded with a drug-releasing 
implant based on nanoengineered Ti wires covered with 
a layer of TNT arrays. The utility of the Zetos system for 
studying drug-release kinetics and transport of drugs in 
bones is demonstrated for the first time. Successful ex vivo 
experiments lead to the conclusion that the release pattern and 
molecular disposition of drugs can be precisely estimated in 
the bone core with respect to time and location, showing the 
potential of this technology to predict a real drug concentration 
and distribution in bone, which is not possible with existing 
in vitro models. This method has the potential to provide 
new knowledge to understand drug distribution in complex 
bone environment and to considerably improve existing 
technologies for local administration in bone, including 
solving some critical problems in bone therapy and orthopedic 
implants. TNT–Ti wire can be considered as a safe drug-
releasing implant for localized drug delivery in bone with the 
potential for clinical application in a range of bone therapies, 
including those for bone infection, bone inflammation, and 
bone cancer.
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